About this trial
Invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are common and serious in immunocompromised subjects and particularly organ transplant patients. There is little recent data in heart transplantation, particularly on the incidence and risk factors of fungal infections. . It is therefore important to have recent data on incidence, risk and prognostic factors in order to improve the management of this severe complication.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patient ≥18 years old
Heart transplant
Invasive fungal infection with filamentous fungi during the period from January 1, 2008 to December 31, 2022
Invasive aspergillosis
Disqualifiers
Patient having expressed his opposition to participating in the study
Patient not having a liver transplant
Subject under guardianship, curatorship or safeguard of justice.
Trial population
Adult patient ≥18 years old having heart transplant and invasive fungal infection with filamentous fungi during the period from January 1, 2008 to December 31, 2022
Trial design
Case-control
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
To identify the incidence, risk factors and prognostic factors associated with invasive fungal infections caused by filamentous fungi in heart transplant patients.
1. Incidence: number of cases of invasive fungal infection compared to the number of heart transplant patients per year in the study centers 2. Risk factors: Case-control study. Clinical, microbiological or radiological factors statistically associated with cases of invasive fungal infection compared to controls. 3. Prognostic factors: Clinical, microbiological or radiological factors of invasive fungal infections associated with mortality at the 12th week.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.